<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03595410</url>
  </required_header>
  <id_info>
    <org_study_id>Laryngeal carcinoma</org_study_id>
    <nct_id>NCT03595410</nct_id>
  </id_info>
  <brief_title>Nomograms to Precisely Predict Conditional Risk of Recurrence for Patients With Laryngeal Cancer</brief_title>
  <official_title>Development and Validation of Nomograms to Precisely Predict Conditional Risk of Recurrence for Patients With Laryngeal Cancer: a Single-institutional Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First Affiliated Hospital, Sun Yat-Sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      Advanced laryngeal squamous cell carcinoma (SCC) remains a highly morbid and fatal disease
      despite aggressive interventions. Mortality is high in this cohort: laryngeal cancer affects
      over 13 000 patients in the United States, with over 3500 deaths annually.The results of the
      Veterans Affairs Cooperative Studies Program Laryngeal Cancer Trial and subsequent studies
      demonstrated similar overall survival (OS) rates for organ preservation protocols involving
      radiotherapy (RT) or chemoradiotherapy (CRT) when compared to surgery, with the benefit of
      preserving the larynx in a large majority of patients. As such, the use of RT or CRT has
      become the predominant initial intervention for patients with laryngeal SCC.6 However, the
      prognosis of recurrent and persistent laryngeal SCC is particularly dire.In this study, we
      sought to identify preoperative predictors of survival for patients with recurrent or
      persistent laryngeal SCC in order to set patient expectations and address modifiable risk
      factors. Identification of predictors of survival may also identify patients who could
      benefit from novel therapeutic agents in a neo/adjuvant fashion. Herein,we examine a cohort
      of patients with recurrent or persistent laryngeal SCC after definitive RT/CRT who has
      undergone total laryngectomy in order to identify potential preoperative predictors of
      clinical outcomes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Demographic, clinical, and survival data were abstracted. Death was verified via medical
      records and the social security death index. Primary outcome measures were OS (time from
      salvage laryngectomy to death from any cause), disease-specific survival (DSS; time from
      salvage laryngectomy to death from recurrent/persistent laryngeal SCC), and DFS (time from
      salvage laryngectomy to laryngeal SCC recurrence)
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Anticipated">January 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Follow up 5 years</time_frame>
    <description>time from salvage laryngectomy to death from any cause</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Recurrent Laryngeal Cancer</condition>
  <arm_group>
    <arm_group_label>Recurrence laryngeal cancer</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>No recurrence laryngeal cancer</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Recurrence laryngeal cancer</intervention_name>
    <description>Recurrence laryngeal cancer has a wide range of invasion, rapid progression and poor prognosis.</description>
    <arm_group_label>No recurrence laryngeal cancer</arm_group_label>
    <arm_group_label>Recurrence laryngeal cancer</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients with laryngeal cancer
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        patients with a diagnosis of laryngeal squamous cell carcinoma

        Exclusion Criteria:

        multiple primarry malignant neo-plasms
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Genglong Liu</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Affiliated Hospital, Sun Yat-Sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Genglong Liu, MD</last_name>
    <phone>+8615626405844</phone>
    <email>lglong3@mail2.sysu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Genglong Liu</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Genglong Liu, MD</last_name>
      <phone>+8615626405844</phone>
      <email>lglong3@mail2.sysu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>July 13, 2018</study_first_submitted>
  <study_first_submitted_qc>July 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2018</study_first_posted>
  <last_update_submitted>July 13, 2018</last_update_submitted>
  <last_update_submitted_qc>July 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>First Affiliated Hospital, Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>GengLong Liu</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>risk of recurrence</keyword>
  <keyword>Nomograms</keyword>
  <keyword>Laryngeal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Laryngeal Neoplasms</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

